Latham, N.Y.-based AngioDynamics’ newly developed, FDA-cleared Auryon atherectomy system uses lasers to treat PAD lesions and occlusions, both above and below the knee in any type or length with minimal impact on the vessel walls, according to a news release. Its uses in treating PAD include critical limb ischemia (CLI) and in-stent restenosis (ISR).
The system uses a 355nm wavelength laser platform, performing short UV laser pulses with targeted biological reactions for treating PAD while minimizing the reisk of perforation and preserving the ability to vaporize lesions without thermal ablation.
AngioDynamics said the Auryon system features aspiration and off-set capability in certain catheter sizes so clinicinas can address the risk of embolization while treating all types of lesions.
“We strongly believe the Auryon atherectomy system is a game-changer for the treatment of PAD, representing a true technological advancement in the treatment of these widespread and potentially fatal conditions,” AngioDynamics president & CEO Jim Clemmer said in the release. “We have already seen a very positive response from initial users of the Auryon system, which has led to a rapid expansion of markets and geographies. AngioDynamics is proud to make the Auryon atherectomy system, and its solid-state laser technology, available to providers and patients nationwide.”